Katrine Bosley was Appointed as Chief Executive Officer at Editas-Medicine

Date of management change: June 15, 2014 

What Happened?

Cambridge, MA-based Editas-Medicine Appointed Katrine Bosley as Chief Executive Officer

 

About the Company

What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We`re a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Our goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer. We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine `Editors`, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we`ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.

 

About the Person

Katrine Bosley is the CEO of Editas Medicine, Chairman of Genocea & a Board member of Galapagos & Scholar Rock. Katrine Bosley joined Editas Medicine as CEO in 2014. Before Editas, Katrine was the CEO of Avila Therapeutics (acquired by Celgene), a biopharmaceutical company that pioneered a class of medicines known as targeted covalent drugs. She was also recently the Entrepreneur-in-Residence at The Broad Institute, a biomedical and genomic research center. Earlier, she was VP, Business Development at Adnexus Therapeutics and then VP, Strategic Operations after its acquisition by Bristol-Myers Squibb. Prior to that, at Biogen Idec Katrine held roles in business development, commercial operations, and portfolio strategy in the U.S. and Europe and led numerous transactions there, including the alliance for Tysabri® (natalizumab), a treatment for multiple sclerosis. Katrine was also part of the healthcare team at the venture firm Highland Capital Partners and was an early employee of Alkermes. Katrine is a graduate of Cornell University. In addition to her role at Editas, Katrine currently serves as Chairman of the Board of Genocea Biosciences (NASDAQ: GNCA) and is a member of the Board of Directors of Galapagos NV (EURONEXT: GLPG) and of Scholar Rock, LLC, and is a review committee member for the Translation Fund of the Wellcome Trust.  

 

Info Source

Press Release

 
 

Other IT executives who recently changed jobs as well: Cowart Sherry, Brese Rebecca, Bremer Henning, Elenio Paul, Truvillion Jeremy, Hill Kesha, Johnson Meredith, Boylan Katherine, Camarillo Ellen, Dale Jeff, Zhang James

You can find the full directory of IT executives here.

How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.